A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis

Atherosclerosis

Volumn 224, Issue 2, 2012, Pages 302-308

  van der Vorst, Emiel P C ^a   Keijbeck, Anke A ^a   de Winther, Menno P J ^a,b   Donners, Marjo M P C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

A disintegrin and metalloproteases; Angiogenesis; Atherosclerosis; Inflammation; Shedding

Indexed keywords

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; BIOLOGICAL MARKER; NOTCH RECEPTOR; PROTEIN ADAM15; PROTEIN ADAM17; PROTEIN ADAM19; PROTEIN ADAM28; PROTEIN ADAM33; PROTEIN ADAM8; PROTEIN ADAM9; UNCLASSIFIED DRUG;

ANGIOGENESIS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW;

ADAM PROTEINS; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD VESSELS; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84866531672     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.04.023     Document Type: Review

References (58)

1. Reiss K., Saftig P. The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 2009, 20:126-137.
2. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol Aspects Med 2008, 29:258-289.
3. Duffy M.J., McKiernan E., O'Donovan N., McGowan P.M. The role of ADAMs in disease pathophysiology. Clin Chim Acta 2009, 403:31-36.
4. Reiss K., Ludwig A., Saftig P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther 2006, 111:985-1006.
5. Le Gall S.M., Bobe P., Reiss K., Horiuchi K., Niu X.D., Lundell D., et al. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell 2009, 20:1785-1794.
6. Sahin U., Weskamp G., Kelly K., Zhou H.M., Higashiyama S., Peschon J., et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004, 164:769-779.
7. Barlic J., Zhu W., Murphy P.M. Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion. J Immunol 2009, 182:7928-7936.
8. Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. Semin Cell Dev Biol 2009, 20:138-145.
9. Tellier E., Canault M., Rebsomen L., Bonardo B., Juhan-Vague I., Nalbone G., et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res 2006, 312:3969-3980.
10. Lemaire-Ewing S., Lagrost L., Neel D. Lipid rafts: a signalling platform linking lipoprotein metabolism to atherogenesis. Atherosclerosis 2012, 221:303-310.
11. Chen J.X., Chen Y., DeBusk L., Lin W., Lin P.C. Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am J Physiol Heart Circ Physiol 2004, 287:H187-H195.
12. Tang J., Zarbock A., Gomez I., Wilson C.L., Lefort C.T., Stadtmann A., et al. Adam17-dependent shedding limits early neutrophil influx but does not alter early monocyte recruitment to inflammatory sites. Blood 2011, 118:786-794.
13. Donners M.M., Wolfs I.M., Olieslagers S., Mohammadi-Motahhari Z., Tchaikovski V., Heeneman S., et al. A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:2188-2195.
14. Swendeman S., Mendelson K., Weskamp G., Horiuchi K., Deutsch U., Scherle P., et al. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res 2008, 103:916-918.
15. Koenen R.R., Pruessmeyer J., Soehnlein O., Fraemohs L., Zernecke A., Schwarz N., et al. Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood 2009, 113:4799-4809.
16. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009, 16:196-208.
17. Hartmann D., de Strooper B., Serneels L., Craessaerts K., Herreman A., Annaert W., et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 2002, 11:2615-2624.
18. Gooz P., Gooz M., Baldys A., Hoffman S. ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. Biochem Biophys Res Commun 2009, 380:33-38.
19. Kwak H.I., Mendoza E.A., Bayless K.J. ADAM17 co-purifies with TIMP-3 and modulates endothelial invasion responses in three-dimensional collagen matrices. Matrix Biol 2009, 28:470-479.
20. Guaiquil V.H., Swendeman S., Zhou W., Guaiquil P., Weskamp G., Bartsch J.W., et al. ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med (Berl) 2010, 88:497-505.
21. Guaiquil V., Swendeman S., Yoshida T., Chavala S., Campochiaro P.A., Blobel C.P. ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol 2009, 29:2694-2703.
22. Horiuchi K., Weskamp G., Lum L., Hammes H.P., Cai H., Brodie T.A., et al. Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol 2003, 23:5614-5624.
23. Glomski K., Monette S., Manova K., De Strooper B., Saftig P., Blobel C.P. Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures. Blood 2011, 118:1163-1174.
24. Weskamp G., Mendelson K., Swendeman S., Le Gall S., Ma Y., Lyman S., et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res 2010, 106:932-940.
25. Virmani R., Kolodgie F.D., Burke A.P., Finn A.V., Gold H.K., Tulenko T.N., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005, 25:2054-2061.
26. Ludwig A., Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemostasis 2007, 97:694-703.
27. Gough P.J., Garton K.J., Wille P.T., Rychlewski M., Dempsey P.J., Raines E.W. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004, 172:3678-3685.
28. Garton K.J., Gough P.J., Philalay J., Wille P.T., Blobel C.P., Whitehead R.H., et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 2003, 278:37459-37464.
29. Tsakadze N.L., Sithu S.D., Sen U., English W.R., Murphy G., D'Souza S.E. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 2006, 281:3157-3164.
30. Ballantyne C.M., Entman M.L. Soluble adhesion molecules and the search for biomarkers for atherosclerosis. Circulation 2002, 106:766-767.
31. Long C., Wang Y., Herrera A.H., Horiuchi K., Walcheck B. In vivo role of leukocyte ADAM17 in the inflammatory and host responses during E. coli-mediated peritonitis. J Leukocyte Biology 2010, 87:1097-1101.
32. Wolfs I.M., Donners M.M., de Winther M.P. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemostasis 2011, 106.
33. Hiasa M., Abe M., Nakano A., Oda A., Amou H., Kido S., et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 2009, 114:4517-4526.
34. Ohishi K., Katayama N., Shiku H., Varnum-Finney B., Bernstein I.D. Notch signalling in hematopoiesis. Semin Cell Dev Biol 2003, 14:143-150.
35. Bell J.H., Herrera A.H., Li Y., Walcheck B. Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol 2007, 82:173-176.
36. Canault M., Peiretti F., Kopp F., Bonardo B., Bonzi M.F., Coudeyre J.C., et al. The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 2006, 187:82-91.
37. Horiuchi K., Kimura T., Miyamoto T., Takaishi H., Okada Y., Toyama Y., et al. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 2007, 179:2686-2689.
38. Stoger J.L., Goossens P., de Winther M.P. Macrophage heterogeneity: relevance and functional implications in atherosclerosis. Curr Vasc Pharmacol 2010, 8:233-248.
39. Etzerodt A., Maniecki M.B., Moller K., Moller H.J., Moestrup S.K. Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukocyte Biology 2010, 88:1201-1205.
40. Garbers C., Janner N., Chalaris A., Moss M.L., Floss D.M., Meyer D., et al. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 2011, 286:14804-14811.
41. Oksala N., Levula M., Airla N., Pelto-Huikko M., Ortiz R.M., Jarvinen O., et al. ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries-Tampere vascular study. Ann Med 2009, 41:279-290.
42. Canault M., Leroyer A.S., Peiretti F., Leseche G., Tedgui A., Bonardo B., et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 2007, 171:1713-1723.
43. Holdt L.M., Thiery J., Breslow J.L., Teupser D. Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008, 28:1097-1103.
44. Holloway J.W., Laxton R.C., Rose-Zerilli M.J., Holloway J.A., Andrews A.L., Riaz Z., et al. ADAM33 expression in atherosclerotic lesions and relationship of ADAM33 gene variation with atherosclerosis. Atherosclerosis 2010, 211:224-230.
45. Levula M., Airla N., Oksala N., Hernesniemi J.A., Pelto-Huikko M., Salenius J.P., et al. ADAM8 and its single nucleotide polymorphism 2662 T/G are associated with advanced atherosclerosis and fatal myocardial infarction: Tampere vascular study. Ann Med 2009, 41:497-507.
46. Bultmann A, Li Z, Wagner S, Gawaz M, Ungerer M, Langer H, et al. Loss of protease activity of ADAM15 abolishes protective effects on plaque progression in atherosclerosis. Int J Cardiol; 152: 382-385.
47. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006, 5:785-799.
48. Duffy M.J., Mullooly M., O'Donovan N., Sukor S., Crown J., Pierce A., et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?. Clin Proteomics 2011, 8:9.
49. Dyczynska E., Sun D., Yi H., Sehara-Fujisawa A., Blobel C.P., Zolkiewska A. Proteolytic processing of delta-like 1 by ADAM proteases. The Journal of biological chemistry 2007, 282:436-444.
50. Charrier-Hisamuddin L., Laboisse C.L., Merlin D. ADAM-15: a metalloprotease that mediates inflammation. FASEB J 2008, 22:641-653.
51. Huovila A.P., Turner A.J., Pelto-Huikko M., Karkkainen I., Ortiz R.M. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005, 30:413-422.
52. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008, 8:929-941.
53. Nagano O., Murakami D., Hartmann D., De Strooper B., Saftig P., Iwatsubo T., et al. Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 2004, 165:893-902.
54. Hundhausen C., Schulte A., Schulz B., Andrzejewski M.G., Schwarz N., von Hundelshausen P., et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 2007, 178:8064-8072.
55. Schwarz N., Pruessmeyer J., Hess F.M., Dreymueller D., Pantaler E., Koelsch A., et al. Requirements for leukocyte transmigration via the transmembrane chemokine CX3CL1. Cell Mol Life Sci 2010, 67:4233-4248.
56. Garton K.J., Gough P.J., Raines E.W. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. Journal of leukocyte biology 2006, 79:1105-1116.
57. McGinn O.J., English W.R., Roberts S., Ager A., Newham P., Murphy G. Modulation of integrin alpha4beta1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration. Cell Biol Int 2011, 35:1043-1053.
58. Dreymueller D., Pruessmeyer J., Groth E., Ludwig A. The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol. 2012 Jun, 91(6-7):472-485.